{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T20:55:07Z","timestamp":1791665707679,"version":"4.3.4"},"reference-count":74,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhltonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Heart and Lung Transplantation"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.healun.2022.12.011","type":"journal-article","created":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T02:34:16Z","timestamp":1671503656000},"page":"423-432","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Assessment and management of allosensitization following heart transplant in adults"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9104-1980","authenticated-orcid":false,"given":"Abhishek","family":"Jaiswal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ersilia M.","family":"DeFilippis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0507-2412","authenticated-orcid":false,"given":"Evan P.","family":"Kransdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0618-6750","authenticated-orcid":false,"given":"Jignesh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9308-3172","authenticated-orcid":false,"given":"Jon A.","family":"Kobashigawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4492-2691","authenticated-orcid":false,"given":"Michelle M.","family":"Kittleson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7754-9953","authenticated-orcid":false,"given":"David A.","family":"Baran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.healun.2022.12.011_bib0001","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/TP.0b013e318273878c","article-title":"Donor-specific antibodies to class II antigens are associated with accelerated cardiac allograft vasculopathy: a three-dimensional volumetric intravascular ultrasound study","volume":"95","author":"Topilsky","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2022.12.011_bib0002","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.healun.2016.10.016","article-title":"Donor-specific anti-HLA antibodies with antibody-mediated rejection and long-term outcomes following heart transplantation","volume":"36","author":"Clerkin","year":"2017","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2022.12.011_bib0003","doi-asserted-by":"crossref","first-page":"e431","DOI":"10.1097\/TP.0000000000002333","article-title":"Understanding the correlation between DSA, complement activation, and antibody-mediated rejection in heart transplant recipients","volume":"102","author":"Zhang","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2022.12.011_bib0004","doi-asserted-by":"crossref","first-page":"e13416","DOI":"10.1111\/ctr.13416","article-title":"De novo donor-specific HLA antibodies in heart transplantation: do transient de novo DSA confer the same risk as persistent de novo DSA?","volume":"32","author":"Moayedi","year":"2018","journal-title":"Clin Transplant"},{"key":"10.1016\/j.healun.2022.12.011_bib0005","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.trre.2018.05.002","article-title":"The clinical impact of donor-specific antibodies in heart transplantation","volume":"32","author":"Barten","year":"2018","journal-title":"Transplant Rev (Orlando)"},{"key":"10.1016\/j.healun.2022.12.011_bib0006","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.healun.2021.08.004","article-title":"Many heart transplant biopsies currently diagnosed as no rejection have mild molecular antibody-mediated rejection-related changes","volume":"41","author":"Halloran","year":"2022","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2022.12.011_bib0007","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3389\/fimmu.2017.00004","article-title":"Significance of anti-HLA antibodies on adult and pediatric heart allograft outcomes","volume":"8","author":"Mangiola","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.healun.2022.12.011_bib0008","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.healun.2011.02.002","article-title":"Current and future challenges in therapy for antibody-mediated rejection","volume":"30","author":"Nair","year":"2011","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2022.12.011_bib0009","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/petr.12606","article-title":"Risk factors for the development of donor-specific antibodies after pediatric heart transplantation","volume":"19","author":"Godown","year":"2015","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.healun.2022.12.011_bib0010","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.12924","article-title":"De novo DQ donor-specific antibodies are associated with worse outcomes compared to non-DQ de novo donor-specific antibodies following heart transplantation","volume":"31","author":"Cole","year":"2017","journal-title":"Clin Transplant"},{"key":"10.1016\/j.healun.2022.12.011_bib0011","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.humimm.2008.10.013","article-title":"Peripheral blood B cells producing donor-specific HLA antibodies in vitro","volume":"70","author":"Han","year":"2009","journal-title":"Hum Immunol"},{"key":"10.1016\/j.healun.2022.12.011_bib0012","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1111\/ajt.12478","article-title":"Class II HLA epitope matching-A strategy to minimize de novo donor-specific antibody development and improve outcomes","volume":"13","author":"Wiebe","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.healun.2022.12.011_bib0013","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.humimm.2010.10.013","article-title":"Pre- and posttransplantation allosensitization in heart allograft recipients: major impact of de novo alloantibody production on allograft survival","volume":"72","author":"Ho","year":"2011","journal-title":"Hum Immunol"},{"key":"10.1016\/j.healun.2022.12.011_bib0014","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1600-6143.2010.03383.x","article-title":"De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival","volume":"11","author":"Smith","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.healun.2022.12.011_bib0015","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/TP.0000000000000869","article-title":"The influence of immunosuppressive agents on the risk of de novo donor-specific HLA antibody production in solid organ transplant recipients","volume":"100","author":"O'Leary","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2022.12.011_bib0016","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1016\/j.jacc.2013.06.054","article-title":"Influence of race\/ethnic differences in pre-transplantation panel reactive antibody on outcomes in heart transplant recipients","volume":"62","author":"Morris","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.healun.2022.12.011_bib0017","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.healun.2014.12.012","article-title":"Race and ethnic differences in the epidemiology and risk factors for graft failure after heart transplantation","volume":"34","author":"Morris","year":"2015","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2022.12.011_bib0018","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.healun.2017.11.003","article-title":"Racial differences in the development of de-novo donor-specific antibodies and treated antibody-mediated rejection after heart transplantation","volume":"37","author":"Cole","year":"2018","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2022.12.011_bib0019","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.humimm.2013.06.022","article-title":"Frequent development of subclinical chronic antibody-mediated rejection within 1 year after renal transplantation with pre-transplant positive donor-specific antibodies and negative CDC crossmatches","volume":"74","author":"Yamanaga","year":"2013","journal-title":"Hum Immunol"},{"key":"10.1016\/j.healun.2022.12.011_bib0020","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/TP.0000000000000821","article-title":"Deleterious impact of donor-specific anti-HLA antibodies toward HLA-Cw and HLA-DP in kidney transplantation","volume":"100","author":"Bachelet","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2022.12.011_bib0021","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.healun.2010.08.020","article-title":"Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients","volume":"30","author":"Chin","year":"2011","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2022.12.011_bib0022","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1111\/ajt.14231","article-title":"Allosensitization following bone graft","volume":"17","author":"O'Sullivan","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1016\/j.healun.2022.12.011_bib0023","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.healun.2015.10.006","article-title":"The use of circulating donor specific antibody to predict biopsy diagnosis of antibody-mediated rejection and to provide prognostic value after heart transplantation in children","volume":"35","author":"Ware","year":"2016","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2022.12.011_bib0024","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1111\/ajt.13295","article-title":"Assessing antibody strength: comparison of MFI, C1q, and titer information","volume":"15","author":"Tambur","year":"2015","journal-title":"Am J Transplant"},{"issue":"Suppl 1","key":"10.1016\/j.healun.2022.12.011_bib0025","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1097\/TP.0000000000001817","article-title":"HLA diagnostics: evaluating DSA strength by titration","volume":"102","author":"Tambur","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2022.12.011_bib0026","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.healun.2015.03.002","article-title":"Late antibody-mediated rejection after heart transplantation: mortality, graft function, and fulminant cardiac allograft vasculopathy","volume":"34","author":"Coutance","year":"2015","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2022.12.011_bib0027","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13121","article-title":"The role of complement-fixing donor-specific antibodies identified by a C1q assay after heart transplantation","volume":"31","author":"Farrero Torres","year":"2017","journal-title":"Clin Transplant"},{"key":"10.1016\/j.healun.2022.12.011_bib0028","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.trim.2018.03.002","article-title":"Complement-fixing donor-specific anti-HLA antibodies and kidney allograft failure","volume":"49","author":"Cazarote","year":"2018","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.healun.2022.12.011_bib0029","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1097\/TP.0000000000001487","article-title":"Clinical outcome of patients with de novo C1q-binding donor-specific HLA antibodies after renal transplantation","volume":"101","author":"Bamoulid","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2022.12.011_bib0030","article-title":"Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: a systematic review and meta-analysis","volume":"15","author":"Bouquegneau","year":"2018","journal-title":"PLoS Med"},{"key":"10.1016\/j.healun.2022.12.011_bib0031","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.healun.2018.01.1291","article-title":"The management of antibodies in heart transplantation: an ISHLT consensus document","volume":"37","author":"Kobashigawa","year":"2018","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2022.12.011_bib0032","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1111\/j.1600-6143.2009.02748.x","article-title":"Correlation of donor-specific antibodies, complement and its regulators with graft dysfunction in cardiac antibody-mediated rejection","volume":"9","author":"Tan","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.healun.2022.12.011_bib0033","first-page":"413","article-title":"Immunoglobulin G subclass analysis of HLA donor specific antibodies in heart and renal transplant recipients","author":"Cicciarelli","year":"2013","journal-title":"Clin Transpl"},{"key":"10.1016\/j.healun.2022.12.011_bib0034","doi-asserted-by":"crossref","first-page":"e1415","DOI":"10.1002\/cti2.1415","article-title":"A new flow cytometry assay identifies recipient IgG subtype antibodies binding donor cells: increasing donor availability for highly sensitised patients","volume":"11","author":"Rao","year":"2022","journal-title":"Clin Transl Immunology"},{"key":"10.1016\/j.healun.2022.12.011_bib0035","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1093\/ehjci\/jeab212","article-title":"Speckle-tracking-based global longitudinal and circumferential strain detect early signs of antibody-mediated rejection in heart transplant patients","volume":"23","author":"Ciarka","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.healun.2022.12.011_bib0036","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.3389\/fimmu.2018.02673","article-title":"Long-lived plasma cells in mice and men","volume":"9","author":"Brynjolfsson","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.healun.2022.12.011_bib0037","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1111\/ajt.12308","article-title":"Cryptic B cell response to renal transplantation","volume":"13","author":"Lynch","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.healun.2022.12.011_bib0038","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.healun.2003.09.016","article-title":"Effect of late medication non-compliance on outcome after heart transplantation: a 5-year follow-up","volume":"23","author":"Dobbels","year":"2004","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2022.12.011_bib0039","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/tri.13442","article-title":"Allosensitization after transplant failure: the role of graft nephrectomy and immunosuppression - a retrospective study","volume":"32","author":"Lucisano","year":"2019","journal-title":"Transpl Int"},{"key":"10.1016\/j.healun.2022.12.011_bib0040","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/tri.12330","article-title":"Conversion to mammalian target of rapamycin inhibitors increases risk of de novo donor-specific antibodies","volume":"27","author":"Croze","year":"2014","journal-title":"Transpl Int"},{"key":"10.1016\/j.healun.2022.12.011_bib0041","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/ajt.13588","article-title":"Everolimus initiation with early calcineurin inhibitor withdrawal in de novo heart transplant recipients: three-year results from the randomized SCHEDULE study","volume":"16","author":"Andreassen","year":"2016","journal-title":"Am J Transplant"},{"key":"10.1016\/j.healun.2022.12.011_bib0042","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1600-6143.2005.01178.x","article-title":"A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody","volume":"6","author":"Stegall","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.healun.2022.12.011_bib0043","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/trf.12923","article-title":"Efficacy of plasmapheresis on donor-specific antibody reduction by HLA specificity in post-kidney transplant recipients","volume":"55","author":"Yamada","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.healun.2022.12.011_bib0044","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1177\/0391398818823763","article-title":"Antibody-mediated rejection after cardiac transplant: treatment with immunoadsorption, intravenous immunoglobulin, and anti-thymocyte globulin","volume":"42","author":"Sipahi","year":"2019","journal-title":"Int J Artif Organs"},{"key":"10.1016\/j.healun.2022.12.011_bib0045","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1002\/ehf2.13409","article-title":"Treatment of donor-specific antibody-mediated rejection after heart transplantation by IgM-enriched human immunoglobulin","volume":"8","author":"Immohr","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.healun.2022.12.011_bib0046","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1056\/NEJMoa1612567","article-title":"IgG endopeptidase in highly sensitized patients undergoing transplantation","volume":"377","author":"Jordan","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.healun.2022.12.011_bib0047","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/tri.13613","article-title":"An extension of the RITUX-ERAH study, multicenter randomized clinical trial comparing rituximab to placebo in acute antibody-mediated rejection after renal transplantation","volume":"33","author":"Bailly","year":"2020","journal-title":"Transpl Int"},{"key":"10.1016\/j.healun.2022.12.011_bib0048","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1111\/ajt.15514","article-title":"Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant","volume":"19","author":"Redfield","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.healun.2022.12.011_bib0049","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1097\/TP.0b013e31824612df","article-title":"Durability of antibody removal following proteasome inhibitor-based therapy","volume":"93","author":"Everly","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2022.12.011_bib0050","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/ajt.13050","article-title":"Prospective iterative trial of proteasome inhibitor-based desensitization","volume":"15","author":"Woodle","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.healun.2022.12.011_bib0051","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.healun.2015.01.982","article-title":"Reduced HLA Class II antibody response to proteasome inhibition in heart transplantation","volume":"34","author":"Khuu","year":"2015","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2022.12.011_bib0052","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.healun.2021.03.001","article-title":"Impact of carfilzomib-based desensitization on heart transplantation of sensitized candidates","volume":"40","author":"Sriwattanakomen","year":"2021","journal-title":"J Heart Lung Transplant"},{"issue":"Suppl 4","key":"10.1016\/j.healun.2022.12.011_bib0053","doi-asserted-by":"crossref","first-page":"S410","DOI":"10.1016\/j.healun.2022.01.1033","article-title":"Significant reduction of donor specific antibodies in heart transplant recipients treated with proteasome inhibitors for antibody mediated rejection","volume":"41","author":"Horn","year":"2022","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2022.12.011_bib0054","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.4049\/jimmunol.1203261","article-title":"In kidney transplant patients, alemtuzumab but not basiliximab\/low-dose rabbit anti-thymocyte globulin induces B cell depletion and regeneration, which associates with a high incidence of de novo donor-specific anti-HLA antibody development","volume":"191","author":"Todeschini","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.healun.2022.12.011_bib0055","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/978-94-024-0921-5_4","article-title":"Regulation of IL-6 in immunity and diseases","volume":"941","author":"Tanaka","year":"2016","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.healun.2022.12.011_bib0056","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1111\/ajt.14228","article-title":"Assessment of tocilizumab (anti-interleukin-6 receptor monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant glomerulopathy in HLA-sensitized renal allograft recipients","volume":"17","author":"Choi","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1016\/j.healun.2022.12.011_bib0057","doi-asserted-by":"crossref","first-page":"e13908","DOI":"10.1111\/ctr.13908","article-title":"Early effects of first-line treatment with anti-interleukin-6 receptor antibody tocilizumab for chronic active antibody-mediated rejection in kidney transplantation","volume":"34","author":"Lavacca","year":"2020","journal-title":"Clin Transplant"},{"key":"10.1016\/j.healun.2022.12.011_bib0058","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10194359","article-title":"Tocilizumab and desensitization in kidney transplant candidates: personal experience and literature review","volume":"10","author":"Weinhard","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.healun.2022.12.011_bib0059","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1111\/ajt.16420","article-title":"Complement inhibition for prevention of antibody-mediated rejection in immunologically high-risk heart allograft recipients","volume":"21","author":"Patel","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1016\/j.healun.2022.12.011_bib0060","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/TP.0000000000000592","article-title":"A phase I\/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients","volume":"99","author":"Vo","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2022.12.011_bib0061","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1111\/ajt.13871","article-title":"Plasma-derived C1 esterase inhibitor for acute antibody-mediated rejection following kidney transplantation: results of a randomized double-blind placebo-controlled pilot study","volume":"16","author":"Montgomery","year":"2016","journal-title":"Am J Transplant"},{"key":"10.1016\/j.healun.2022.12.011_bib0062","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1111\/ajt.13663","article-title":"C1 inhibitor in acute antibody-mediated rejection nonresponsive to conventional therapy in kidney transplant recipients: a pilot study","volume":"16","author":"Viglietti","year":"2016","journal-title":"Am J Transplant"},{"key":"10.1016\/j.healun.2022.12.011_bib0063","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.healun.2022.12.011_bib0064","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/ajt.13045","article-title":"Neutralizing BAFF\/APRIL with atacicept prevents early DSA formation and AMR development in T cell depletion induced nonhuman primate AMR model","volume":"15","author":"Kwun","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.healun.2022.12.011_bib0065","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJMoa1506027","article-title":"Belatacept and long-term outcomes in kidney transplantation","volume":"374","author":"Vincenti","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.healun.2022.12.011_bib0066","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/ajt.15067","article-title":"Dual targeting: Combining costimulation blockade and bortezomib to permit kidney transplantation in sensitized recipients","volume":"19","author":"Burghuber","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.healun.2022.12.011_bib0067","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1111\/ajt.15319","article-title":"Abatacept as rescue immunosuppression after calcineurin inhibitor treatment failure in renal transplantation","volume":"19","author":"Badell","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.healun.2022.12.011_bib0068","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1111\/ajt.14939","article-title":"Comparison of de novo IgM and IgG anti-HLA DSAs between belatacept- and calcineurin-treated patients: An analysis of the BENEFIT and BENEFIT-EXT trial cohorts","volume":"18","author":"Everly","year":"2018","journal-title":"Am J Transplant"},{"key":"10.1016\/j.healun.2022.12.011_bib0069","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1111\/ajt.14733","article-title":"Safety, immunogenicity, pharmacokinetics, and efficacy of degradation of anti-HLA antibodies by IdeS (imlifidase) in chronic kidney disease patients","volume":"18","author":"Lorant","year":"2018","journal-title":"Am J Transplant"},{"key":"10.1016\/j.healun.2022.12.011_bib0070","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/TP.0000000000003712","article-title":"Angiotensin II Type 1 receptor antibody-mediated rejection following orthotopic heart transplant: a single-center experience","volume":"106","author":"Moreno","year":"2022","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2022.12.011_bib0071","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/MOT.0000000000000335","article-title":"Non-HLA antibodies in transplantation: when do they matter?","volume":"21","author":"Philogene","year":"2016","journal-title":"Curr Opin Organ Transplant"},{"key":"10.1016\/j.healun.2022.12.011_bib0072","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1097\/TP.0000000000003551","article-title":"A comprehensive overview of the clinical relevance and treatment options for antibody-mediated rejection associated with non-HLA antibodies","volume":"105","author":"Kardol-Hoefnagel","year":"2021","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2022.12.011_bib0073","doi-asserted-by":"crossref","DOI":"10.1074\/mcp.M110.000497","article-title":"Protein microarrays discover angiotensinogen and PRKRIP1 as novel targets for autoantibodies in chronic renal disease","volume":"10","author":"Butte","year":"2011","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.healun.2022.12.011_bib0074","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1399-0039.2009.01276.x","article-title":"Role of non-HLA genetic variants in end-stage renal disease","volume":"74","author":"Ranganath","year":"2009","journal-title":"Tissue Antigens"}],"container-title":["The Journal of Heart and Lung Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053249822022586?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053249822022586?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T08:47:18Z","timestamp":1760950038000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053249822022586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":74,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S1053249822022586"],"URL":"https:\/\/doi.org\/10.1016\/j.healun.2022.12.011","relation":{},"ISSN":["1053-2498"],"issn-type":[{"value":"1053-2498","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment and management of allosensitization following heart transplant in adults","name":"articletitle","label":"Article Title"},{"value":"The Journal of Heart and Lung Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.healun.2022.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society for Heart and Lung Transplantation. All rights reserved.","name":"copyright","label":"Copyright"}]}}